Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

PURPOSE To determine the toxicity, pharmacokinetics, response rate, and response duration of intravenous (i.v.) administration of recombinant, humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) plus cisplatin (CDDP) in a phase II, open-label, multicenter clinical trial for patients with HER2/neu-overexpressing metastatic breast cancer. PATIENTS AND METHODS The study population consisted of extensively pretreated advanced breast cancer patients with HER2/neu overexpression and disease progression during standard chemotherapy. Patients received a loading dose of rhuMAb HER2 (250 mg i.v.) on day 0, followed by weekly doses of 100 mg i.v. for 9 weeks. Patients received CDDP (75 mg/m2) on days 1, 29, and 57. RESULTS Of 37 patients assessable for response, nine (24.3%) achieved a PR, nine (24.3%) had a minor response or stable disease, and disease progression occurred in 19 (51.3%). The median response duration was 5.3 months (range, 1.6-18). Grade III or IV toxicity was observed in 22 of 39 patients (56%). The toxicity profile reflected that expected from CDDP alone with the most common toxicities being cytopenias (n = 10), nausea/vomiting (n = 9), and asthenia (n = 5). Mean pharmacokinetic parameters of rhuMAb HER2 were unaltered by coadministration of CDDP. CONCLUSION The use of rhuMAb HER2 in combination with CDDP in patients with HER2/neu-overexpressing metastatic breast cancer results in objective clinical response rates higher than those reported previously for CDDP alone, or rhuMAb HER2 alone. In addition, the combination results in no apparent increase in toxicity. Finally, the pharmacology of rhuMAb HER2 was unaffected by coadministration with CDDP.

[1]  Takuma Sasaki,et al.  Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. , 1991, Cancer research.

[2]  A. Eastman,et al.  Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha. , 1992, The Journal of clinical investigation.

[3]  N. Bachur,et al.  High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. , 1980, Cancer clinical trials.

[4]  E. Felip,et al.  Overexpression of c‐erbB‐2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy , 1995, Cancer.

[5]  M. Pike,et al.  Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. , 1994, Cancer research.

[6]  A. Gazdar,et al.  Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. , 1993, Journal of the National Cancer Institute.

[7]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[8]  B. Groner,et al.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.

[9]  C. Macleod,et al.  Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. , 1990, The Journal of clinical investigation.

[10]  Yosef Yarden,et al.  A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.

[11]  R. Finn,et al.  The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells , 1997, Oncogene.

[12]  D. Slamon,et al.  Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. , 1994, Oncogene.

[13]  S. Lippard,et al.  Repair of cisplatin--DNA adducts by the mammalian excision nuclease. , 1996, Biochemistry.

[14]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Sela,et al.  Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. , 1988, Journal of the National Cancer Institute.

[16]  A. Ullrich,et al.  Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. , 1990, Cancer research.

[17]  A. Muscella,et al.  Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades. , 1993, Cancer letters.

[18]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[19]  S. Wingren,et al.  Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. , 1994, Cytometry.

[20]  P. Toy,et al.  A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. , 1991, Cancer research.

[21]  D. Slamon,et al.  Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. , 1992, Oncogene.

[22]  R Akita,et al.  Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. , 1993, Cancer research.

[23]  R. Bast,et al.  Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. , 1991 .

[24]  D. Crothers,et al.  The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately equal to 40 degrees toward the major groove. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Arteaga,et al.  p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. , 1994, Cancer research.

[26]  N. Ibrahim,et al.  Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. , 1995, Journal of the National Cancer Institute.

[27]  J. Roberts,et al.  Cross-linking of Complementary Strands of DNA in Mammalian Cells by Antitumour Platinum Compounds , 1972, Nature.

[28]  B. Rosenberg.  Possible mechanisms for the antitumor activity of platinum coordination complexes. , 1975, Cancer chemotherapy reports.

[29]  R. Gelman,et al.  Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D Tripathy,et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Lippard,et al.  Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin , 1995, Nature.

[32]  D. Horsfall,et al.  Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Marshall,et al.  Preclinical and clinical experience with cisplatin resistance. , 1995, Hematology/oncology clinics of North America.

[34]  J. Izbicki,et al.  Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.

[35]  M. Fernö,et al.  ERBB2 amplification in breast cancer with a high rate of proliferation. , 1991, Oncogene.

[36]  G. Hortobagyi,et al.  Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. , 1978, Cancer treatment reports.

[37]  C. Kotts,et al.  ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. , 1990, Journal of immunological methods.

[38]  R. Wittes,et al.  Cisplatin in the treatment of metastatic breast carcinoma A prospective randomized trial of two dosage schedules , 1982, American journal of clinical oncology.

[39]  V. Chinchilli,et al.  Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  T. Visakorpi,et al.  Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.

[41]  L. Demers,et al.  Serial serum c‐erbB‐2 levels in patients with breast carcinoma , 1996, Cancer.